NCT05042609

A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

A Phase 3 Randomized, Active-Controlled, Double-Masked Study to Evaluate the Safety and Efficacy of TRS01 Eye Drops in the Treatment of Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 142 (actual)
• Sponsor: Tarsier Pharma · Industry
• Sex: All
• Age: 0 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate the efficacy and safety of TRS01 eye drops compared to active comparator in subjects with active non-infectious anterior uveitis with or without uveitic glaucoma

Conditions

• Non-infectious Anterior Uveitis
• Uveitic Glaucoma

Interventions

Type	Name	Description
DRUG	TRS01	TRS01 eye drops Dosed four times a day (QID)
DRUG	FDA approved steroid eye drop (masked)	FDA approved steroid eye drop Dosed four times a day (QID)

Timeline

• Start date: 2021-09-20
• Primary completion: 2023-06-29
• Completion: 2023-06-29
• First posted: 2021-09-13
• Last updated: 2023-08-28

Locations

30 sites across 3 countries: United States, France, Germany

Regulatory

• FDA-regulated drug study